Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index; 102 of the 170 sources its claims cite were checked for support.

Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies

Open access

Abstract

PURPOSE OF REVIEW: The goal of this review is to evaluate the evolving role of triglycerides (TGs) and TG-rich lipoproteins (TRLs) in cardiovascular disease (CVD) risk and prevention. We examine the mechanistic rationale, genetic and epidemiological evidence, and therapeutic potential of targeting TGs in residual risk reduction, particularly in high-risk populations. RECENT FINDINGS: Emerging data from Mendelian randomization studies and large clinical cohorts support a causal link between elevated remnant lipoproteins and atherosclerotic CVD, in which apolipoprotein B may be the principal driver. Although traditional triglyceride-lowering agents have produced mixed results on cardiovascular outcomes, emerging therapies-such as ApoC-III and ANGPTL3 inhibitors-show robust lipid-lowering effects, while selective PPAR modulators have thus far not demonstrated cardiovascular benefit. However, outcome data remain limited. Residual CVD risk persists despite aggressive LDL-C reduction, especially in patients with diabetes, metabolic syndrome, or chronic kidney disease. Selective TG-lowering strategies targeting TRLs-especially those that decrease apolipoprotein B-may provide clinical benefit in high-risk phenotypes. Ongoing trials will clarify whether these promising agents confer meaningful cardiovascular protection and warrant integration into future guidelines.

Overview

CoChat Summary

TL;DR

This narrative review argues that triglycerides and triglyceride-rich lipoproteins are causally related to residual cardiovascular risk, especially when apoB-containing remnants remain elevated despite LDL-C lowering. It concludes that existing triglyceride-lowering drugs have mixed outcome data, while newer apoC-III and ANGPTL3-targeted therapies are promising but still need definitive cardiovascular outcomes evidence.

Key findings

  • Mendelian randomization and large cohort data support a causal link between elevated remnant lipoproteins and atherosclerotic CVD; the paper states that apoB may be the principal driver of this risk.
  • In genetic studies, APOC3 loss-of-function variants are associated with a 40–50% lower risk of ischemic cardiovascular events, and ANGPTL4 inactivating variants with up to a 19% lower risk of CAD.
  • Volanesorsen lowered triglycerides by ~77% in the phase III APPROACH trial in familial chylomicronemia syndrome, and in COMPASS it reduced triglycerides by ~71%; olezarsen phase 2/3 and phase 3 data showed triglyceride reductions of ~60%.
  • Pemafibrate in PROMINENT reduced triglycerides by –26.2% but did not reduce MACE; by contrast, REDUCE-IT with icosapent ethyl reported a 25% reduction in MACE and a 26% reduction in the key secondary endpoint over 4.9 years in over 8,000 high-risk patients.

Methods

  • Narrative review of triglyceride metabolism, epidemiology, genetics, imaging, and therapies for cardiovascular disease prevention.
  • Synthesizes evidence from Mendelian randomization studies, large observational cohorts, and randomized clinical trials across statins, omega-3 fatty acids, fibrates/PPAR-α modulators, apoC-III inhibitors, and ANGPTL3 inhibitors.
  • Main analysis is qualitative and comparative, emphasizing mechanistic rationale and whether outcome benefits track triglyceride lowering versus apoB reduction.

Limitations

  • The paper explicitly states that outcome data remain limited for emerging therapies and that ongoing trials are needed to clarify cardiovascular benefit.
  • It notes that traditional triglyceride-lowering agents have produced mixed results on cardiovascular outcomes.
  • Evident from the text: this is a review, not a new primary study, so it does not present a single original dataset or meta-analytic effect estimate (not stated in the paper).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11886-025-02337-1

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Regulation of lipoprotein lipase (LPL) activity in triglyceride metabolism. Chylomicrons (CM) derived from intestinal absorption and very-low-density lipoproteins (VLDL) secreted by the liver are hydrolyzed by LPL, generating free fatty acids (FFA) for tissue uptake and intermediate-density lipoproteins (IDL), which can be further remodeled into low-density lipoproteins (LDL). LPL activity is positively regulated by fibrates and cofactors including APOC2, APOA5, GPIHBP1, andLMF1 (green box), and inhibited by ANGPTL3, ANGPTL4, ANGPTL8, and APOC3 (red box). Chylomicron remnants and VLDL-derived IDLs are subsequently taken up by the liver, while further remodeling of IDL produces LDL. The balance between these activators and inhibitors determines the efficiency of triglyceride clearance and downstream lipoprotein remodeling. Created in BioRender. Mathai, S. (2025)https://BioRender.com/3tkj41k
Fig. 1 Regulation of lipoprotein lipase (LPL) activity in triglyceride metabolism. Chylomicrons (CM) derived from intestinal absorption and very-low-density lipoproteins (VLDL) secreted by the liver are hydrolyzed by LPL, generating free fatty acids (FFA) for tissue uptake and intermediate-density lipoproteins (IDL), which can be further remodeled into low-density lipoproteins (LDL). LPL activity is positively regulated by fibrates and cofactors including APOC2, APOA5, GPIHBP1, andLMF1 (green box), and inhibited by ANGPTL3, ANGPTL4, ANGPTL8, and APOC3 (red box). Chylomicron remnants and VLDL-derived IDLs are subsequently taken up by the liver, while further remodeling of IDL produces LDL. The balance between these activators and inhibitors determines the efficiency of triglyceride clearance and downstream lipoprotein remodeling. Created in BioRender. Mathai, S. (2025)https://BioRender.com/3tkj41kCC BY · PubMed Central
Fig. 2 General recommendations on lifestyle modifications and identifying secondary causes of hypertriglyceridemia. ASCVD- atherosclerotic cardiovascular disease, TG- triglyceride, wk- week §- consider referral to registered dietician for tailored dietary counseling. Figure created with data from the 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia [65]. Figures created in BioRender. Mathai, S. (2025)https://BioRender.com/k3ux653
Fig. 2 General recommendations on lifestyle modifications and identifying secondary causes of hypertriglyceridemia. ASCVD- atherosclerotic cardiovascular disease, TG- triglyceride, wk- week §- consider referral to registered dietician for tailored dietary counseling. Figure created with data from the 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia [65]. Figures created in BioRender. Mathai, S. (2025)https://BioRender.com/k3ux653CC BY · PubMed Central
Fig. 3 Phenotypic approach for management of hypertriglyceridemia. ASCVD– atherosclerotic cardiovascular disease, DM- diabetes mellitus, IPE- Icosapent ethyl, LDL-C – low density lipoprotein cholesterol, TG- triglyceride. Figure created with data from the 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia [65]. Figures created in BioRender. Mathai, S. (2025)https://BioRender.com/k3ux653
Fig. 3 Phenotypic approach for management of hypertriglyceridemia. ASCVD– atherosclerotic cardiovascular disease, DM- diabetes mellitus, IPE- Icosapent ethyl, LDL-C – low density lipoprotein cholesterol, TG- triglyceride. Figure created with data from the 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia [65]. Figures created in BioRender. Mathai, S. (2025)https://BioRender.com/k3ux653CC BY · PubMed Central

Verification

Claims the paper makes

62 Valid · 6 Not valid · 36 Not checked · 25 Own results and interpretations

75 more claims · 36 with their cited sources checked

Create a free account to see all 129 claims and to verify the 7 references still open.

See all claims — free account
  • It may state two separate claims as one. 47
  • Probably not a substantial claim. 7

Create a free account to see these claims.

Citations

Cites

Show all 94 references

Research works printed but not linked: 2

  1. 16. Meeusen J, Ueda M, Nordestgaard B RA. Lipids and lipoproteins in Tietz Textbook of Laboratory Medicine. Elsevier Inc.; 2021.
  2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (London, England). 2005;366:1267–78.

Cited by

See all 4

Metadata

Authors
Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., Bhatt, D. L., & Slipczuk, L.
Affiliations
  • Albert Einstein College of Medicine (US)
  • Beth Israel Deaconess Medical Center (US)
  • McGill University Health Centre (CA)
  • Aga Khan University (PK)
  • Johns Hopkins University (US)
  • Wake Forest University Health Sciences (US)
  • The University of Queensland (AU)
  • Icahn School of Medicine at Mount Sinai (US)
Corresponding author
Slipczuk, Leandro
Venue
Current Cardiology Reports
Published
2026-01-03
Volume
28
Issue
1
Pages
8-8
ISSN
  • 1523-3782 (ISSN-L)
  • 1534-3170
OpenAlex
W7118079725
Cited by
4
References
94
Citations by year
2026: 4
FWCI
7.68
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Cardiology Reports (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • eCommons - AKU (Aga Khan University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
triglycerides, triglyceride-rich lipoproteins, remnant lipoproteins, cardiovascular disease prevention, atherosclerotic cardiovascular disease, residual cardiovascular risk, apolipoprotein B, ANGPTL3 inhibitors, triglyceride-lowering therapy, diabetes mellitus, metabolic syndrome, chronic kidney disease
MeSH terms
Hypolipidemic Agents, Cardiovascular Diseases, Humans, Lipoproteins, Triglycerides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies. https://app.cochat.ai/papers/10.1007/s11886-025-02337-1
The paper
Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., Bhatt, D. L., & Slipczuk, L. (2026). Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies. Current Cardiology Reports. https://doi.org/10.1007/s11886-025-02337-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.